Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis
June 02, 2015 07:30 ET
|
Melinta Therapeutics
New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more
than 150 other major food companies, retailers, and human and
animal health stakeholders at...
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
May 19, 2015 16:00 ET
|
Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative
impact of obesity on patients' recovery from acute bacterial skin
and skin structure...
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment
April 09, 2015 12:02 ET
|
Melinta Therapeutics
New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of
Health-Related Quality-of-Life (HRQL) in acute bacterial skin and
skin structure infection...
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
February 09, 2015 08:00 ET
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
January 08, 2015 15:08 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the
largest pharmaceutical companies in Brazil, announced that...
Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI
January 07, 2015 13:40 ET
|
Melinta Therapeutics
New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced positive top-line results from the first of two
Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens
September 08, 2014 15:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
provided an update on the Company's innovative ESKAPE Pathogen
Program. The ESKAPE Pathogen
Program leverages Melinta's...
Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae
September 08, 2014 11:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results from in vitro studies that highlight the
potential of delafloxacin, an
investigational fluoroquinolone,...
Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens
September 06, 2014 12:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and
Hartford Hospital today announced in vitro results from an
investigator-sponsored study that highlight delafloxacin's...
Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program
September 06, 2014 12:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results of a Phase 1 study of delafloxacin, an
investigational fluoroquinolone, in healthy adults that...